






Supplemental Figure 1




Inflammation

Supplemental Figure 2



Apoptosis Initiator

Supplemental Figure 3



Apoptosis Executioner

Supp Table 1

	COVID-19	
	ICU	Non-ICU
Asthma	3 (21)	3 (27)
Autoimmune disease	3 (21)	2 (18)
Cancer	1 (7)	3 (27)
COPD	4 (29)	3 (27)
Coronary Artery Disease	2 (14)	6 (55)
Congestive Heart Failure	3 (21)	5 (45)
CKD without dialysis	2 (14)	4 (36)
CKD/ESRD with dialysis	3 (21)	2 (18)
Diabetes Mellitus	4 (29)	4 (36)
Hyperlipidemia	4 (29)	5 (45)
Hypertension	6 (43)	5 (45)
Immune suppression	5 (36)	4 (36)

Supplemental Table 2.

Lymphocyte Monitoring	18+ Normal	Healthy		Covid-19+		Covid-19+ ICU		Covid-19+ Non ICU		
	Range	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
Monocytes	3.1 - 11.3	5.86	0.30	5.78	0.45	4.06	0.37	7.82	0.62	
Lymphocytes	8.6 - 47.2	36.99	2.76	17.44	1.65	11.91	1.48	25.46	2.52	
CD3	60.3 - 90.6	73.30	3.01	70.94	1.54	68.33	1.98	74.61	2.50	
CD20	2.4 - 21.4	10.39	1.06	15.31	1.53	17.08	2.28	12.03	1.93	
CD3-CD16+ or CD56+	2.3 - 24.7	14.13	2.62	10.22	1.09	10.03	1.38	11.00	1.95	
%TBNK		97.82	0.38	96.47	0.44	95.43	0.69	97.64	0.34	
CD3+CD16+ or CD56+	0.3 - 7.9	5.73	0.88	5.75	0.59	5.20	0.89	6.84	0.75	
T Cell Monitoring and Activation										
CD3+/CD4+	28.3 - 69.4	46.52	2.65	46.08	1.61	47.63	2.35	42.89	2.10	
CD3+/CD8+	8.6 - 39.5	21.47	2.14	21.43	1.72	17.60	1.42	27.60	3.33	
CD3+/CD4-/CD8-	0.4 - 5	4.49	0.81	2.77	0.26	2.58	0.30	3.26	0.49	
CD3/alpha-beta	56 - 87.6	67.37	3.17	66.60	1.52	64.33	1.89	69.67	2.65	
CC3/gamma-delta	0.2 - 5.8	3.36	0.81	1.93	0.31	1.50	0.35	2.67	0.58	
DNT/alpha-beta	0.1 - 1.7	1.06	0.12	0.92	0.08	1.02	0.13	0.84	0.09	
DNT/gamma-delta	0.2 - 4.3	3.24	0.79	1.57	0.26	1.21	0.29	2.20	0.47	
CD3+/CD8+/CD57+	1.2 - 17.2	7.31	1.73	8.72	1.30	5.60	0.98	13.39	2.58	
CD3+/HLA-DR	1.0 - 9.6	1.35	0.25	3.31	0.37	3.21	0.31	3.35	0.84	
CD3+/CD25	11.2 - 53.9	12.20	1.20	13.67	0.54	14.05	0.82	12.76	0.60	
T4/T8 Ratio	0.71 - 4.3	2.50	0.25	2.80	0.29	3.25	0.44	2.04	0.30	
T Cell Memory										
CD3/CD4/CD45RO	9.9 - 37.7	26.70	1.77	32.43	1.98	29.27	2.92	35.82	2.61	
CD3/CD4/CD45RA	3.4 - 37.9	23.68	2.19	19.79	2.37	26.12	3.38	10.87	2.30	
CD3/CD8/CD45RO	1.0 - 8.3	6.71	1.00	5.02	0.67	3.41	0.58	7.39	1.28	
CD3/CD8/CD45RA	2.4 - 23	15.09	1.77	16.22	1.54	14.88	1.79	18.73	2.90	
CD4/CRTH2	0.2 - 3.29	1.31	0.14	1.46	0.12	1.41	0.15	1.53	0.21	
CD4/CD45RO/CRTH2	0.07 - 2.97	1.06	0.11	1.13	0.11	1.07	0.15	1.22	0.18	
CD8/CRTH2	<2.43	3.67	1.19	1.72	0.35	1.45	0.40	2.07	0.67	
CD8/CD45RO/CRTH2	<1.45	1.76	0.58	0.72	0.20	0.47	0.12	1.09	0.46	
B Cell Maturation and Subtypes										
CD20/CD5	0.1 - 4.5	0.97	0.16	0.66	0.11	0.65	0.15	0.67	0.18	
CD20/CD27	0.4 - 5.4	1.91	0.26	2.19	0.31	2.23	0.40	1.95	0.54	
CD21 B-cells	73.2 - 95	89.17	0.92	57.27	3.43	53.80	4.66	63.54	5.40	
CD21 dim B-cells	3.7 - 21.1	8.35	0.56	34.03	2.95	35.48	3.85	29.90	4.87	
IgG B-cells	2.5 - 17.4	4.80	0.40	8.21	0.71	7.67	0.78	9.17	1.42	
IgA B-cells	1.5 - 7.3	6.61	0.62	5.55	0.55	5.83	0.86	4.82	0.63	
IgM B-cells	69.1 - 97.6	85.39	0.79	84.49	0.98	84.29	1.24	84.73	1.81	
IgD B-cells	69.0 - 97.6	85.17	1.08	77.97	1.39	77.42	1.54	78.48	2.81	
IgMCD27 B-cells	5.6 - 27.2	13.60	1.43	8.76	0.84	9.02	1.17	8.79	1.36	
Dendritic Cell Monitoring										
DC	0.04 - 0.5	0.17	0.02	0.13	0.03	0.09	0.02	0.19	0.06	
CD11d	32.6 - 86	60.17	3.03	60.89	4.22	50.91	5.82	72.42	5.44	
BDCA2	8.9 - 59.9	31.10	3.35	9.80	1.77	8.02	2.02	13.38	3.27	

Lymphocyte Monitoring	% CD3- Caspase 1		% CD3+ Caspase 1		% CD3+CD4 Caspase 1	
	Nigericin +	Nigericin -	Nigericin +	Nigericin -	Nigericin +	Nigericin -
Monocytes	0.0478	0.2364	0.0034	0.0535	0.0071	0.1902
Lymphocytes	0.1022	0.0938	0.4072	0.1261	0.6053	0.5053
CD3	0.2239	0.0794	0.8922	0.9462	0.0994	0.4799
CD20	0.0708	0.0024	0.4962	0.0883	0.2428	0.2708
CD3-CD16+ or CD56+	0.2281	0.1597	0.0585	0.0033	0.2261	0.0014
%TBNK	0.1822	0.8014	0.0707	0.1585	0.2183	0.2105
CD3+CD16+ or CD56+	0.3994	0.2117	0.1702	0.0738	0.601	0.2402
T Cell Monitoring and Activation						
CD3+/CD4+	0.6709	0.6096	0.1232	0.3913	0.3922	0.4624
CD3+/CD8+	0.608	0.3932	0.3267	0.6263	0.4266	0.7696
CD3+/CD4-/CD8-	0.1454	0.1243	0.1001	0.0153	0.7973	0.019
CD3/alpha-beta	0.4105	0.1811	0.417	0.634	0.0417	0.2595
CC3/gamma-delta	0.0141	0.1712	0.0215	0.0077	0.7028	0.0169
DNT/alpha-beta	0.1929	0.5278	0.593	0.7579	0.9599	0.6647
DNT/gamma-delta	0.0485	0.1002	0.0434	0.0039	0.7021	0.0043
CD3+/CD8+/CD57+	0.1635	0.5568	0.0764	0.1440	0.6246	0.6712
CD3+/HLA-DR	0.0776	0.9094	0.2337	0.8529	0.4494	0.4775
CD3+/CD25	0.8964	0.9711	0.5885	0.2219	0.2188	0.5518
T4/T8 Ratio	0.4452	0.7438	0.1734	0.6015	0.5964	0.7592
T Cell Memory						
CD3/CD4/CD45RO	0.3395	0.8005	0.0094	0.2178	0.0001	0.1708
CD3/CD4/CD45RA	0.5221	0.9367	0.0018	0.0995	0.004	0.1213
CD3/CD8/CD45RO	0.0242	0.1725	0.0948	0.1103	0.5399	0.5101
CD3/CD8/CD45RA	0.0575	0.388	0.9182	0.3908	0.3846	0.4088
CD4/CRTH2	0.7054	0.1075	0.028	0.0371	0.0049	0.0081
CD4/CD45RO/CRTH2	0.6206	0.2372	0.0173	0.03	0.0017	0.007
CD8/CRTH2	0.6995	0.7309	0.7685	0.9211	0.672	0.963
CD8/CD45RO/CRTH2	0.5391	0.1153	0.8389	0.2566	0.5109	0.2389
B Cell Maturation and Subtypes						
CD20/CD5	0.36	0.6781	0.8324	0.2975	0.46	0.3127
CD20/CD27	0.2057	0.0003	0.9959	0.0648	0.0829	0.2098
CD21 B-cells	0.4523	0.5262	0.9629	0.8012	0.5335	0.6533
CD21 dim B-cells	0.5599	0.7177	0.8625	0.813	0.6934	0.9084
IgG B-cells	0.35	0.0271	0.3069	0.0782	0.3498	0.107
IgA B-cells	0.7525	0.3071	0.5451	0.1946	0.8895	0.3013
IgM B-cells	0.9812	0.2815	0.5311	0.1143	0.8302	0.1667
IgD B-cells	0.4499	0.4945	0.5885	0.2219	0.1677	0.1857
IgMCD27 B-cells	0.0964	0.0342	0.183	0.0677	0.9072	0.1732
Dendritic Cell Monitoring						
DC	0.3404	0.5682	0.2457	0.0183	0.9353	0.1088
CD11d	0.113	0.6528	0.0007	0.5627	0.0195	0.8607
BDCA2	0.687	0.003	0.27	0.0051	0.4543	0.0187

Supplementary information on antibodies:

The antibodies utilized from Thermo Fisher Scientific were CD56 SB436 [TULY56], CD45 eF506 [HI130], CD3 FITC [SK7], CD16 PE [B73.1], CD8 PerCP-eF710 [SK1] CD14 PE-CY7 [61D3], CD4 APC [SK-3], CD20 APC-eF780 [2H7] CD25 EF450 [CD25-4E3], CD57 FITC [TBo1], TCR γ - δ PE [B1.1], CD4 PerCP-eF710 [SK-3], CD3 PE-CY7 [SK7], TCR $\alpha\beta$ APC [IP26], HLA-DR AF700 [LN3], CD8 APC-eF780 [SL1], IgD SB436 [IA6-2], IgA FC Secondary Antibody FITC, IgG FC Secondary Antibody PE, IgM PerCP-eF710 [SA-DA4], CD19 PE-CY7 [SJ25C1], CD27 APC [O323], CD5 FITC [UCHT2], CD21 PE [HB5], CD27 PerCP-eF710 [O323], CD45RA FITC [HI100], CD45RO PerCP-eF710 [UCHL1], CD294 APC [BM16], CD4 AF700 [RPA-T4], CD3 FITC [SK7], CD14 FITC [61D3], CD16 FITC [3G8], CD19 FITC [SJ25-C1], CD20 FITC [2H7], CD56 FITC [TULY56], CD34 FITC [4H11], CD11c PE [3.9], HLA-DR PerCP-EF710 [L243], CD303a APC [201A], CD4 SB600 [SK-3], CD45RA FITC [HI100], CD3 PE-CY7 [SK7], CD8 AF700 [SK1], CCR5 APC [NP-6G4], CD25 APC [BC96], CD317 PE [26F8], IL-6 PE-CY7 [MQ2-13A5], MIP1- β APC [FL34Z3L].

The antibodies utilized from BD Bioscience were HLADR BV480 [G46-6], CD38 PerCP-CY5.5 [HIT2], CD28 APC [CD28.2], CD45 APC H7 [2D1], CD278 BV421 [DX29], CXCR5 PerCP-CY5.5 [RF8B2], CD127 BV480 [HIL-7R-M21], CD45RO PerCP-CY5.5 [UCHL1], CD20 APC-H7 [2H7], CD11b BV421 [ICRF44], CD16 FITC [NKP15], MIP1- α PE [11A3], HLA-DR PerPC-Cy5.5 [L243]. TNF- α BV421 [Mab11] was from Biolegend (San Diego, CA).